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OBJECTIVE—This study determined the effects of high glucose
exposure and cytokine treatment on generation of reactive
oxygen species (ROS) and activation of inﬂammatory and apo-
ptotic pathways in human retinal endothelial cells (HRECs).
RESEARCH DESIGN AND METHODS—Glucose consump-
tion of HRECs, human retinal pigment epithelial cells (HRPEs),
and human Mu ¨ller cells (HMCs) under elevated glucose condi-
tions was measured and compared with cytokine treatment.
Production of ROS in HRECs was examined using 5-(and-6)-
chloromethyl-2,7-dichlorodihydroﬂuorescein diacetate (CM-
H2DCFDA), spin-trap electron paramagnetic resonance, and
MitoTracker Red staining after high glucose and cytokine treat-
ment. The activation of different signaling cascades, including the
mitogen-activated protein kinase pathways, tyrosine phosphory-
lation pathways, and apoptosis by high glucose and cytokines in
HRECs, was determined.
RESULTS—HRECs, in contrast to HRPEs and HMCs, did not
increase glucose consumption in response to increasing glucose
concentrations. Exposure of HRECs to 25 mmol/l glucose did not
stimulate endogenous ROS production, activation of nuclear
factor-B (NF-B), extracellular signal–related kinase (ERK),
p38 and Jun NH2-terminal kinase (JNK), tyrosine phosphoryla-
tion, interleukin (IL)-1, or tumor necrosis factor- (TNF-)
production and only slightly affected apoptotic cell death path-
ways compared with normal glucose (5 mmol/l). In marked
contrast, exposure of HRECs to proinﬂammatory cytokines IL-1
or TNF- increased glucose consumption, mitochondrial super-
oxide production, ERK and JNK phosphorylation, tyrosine phos-
phorylation, NF-B activation, and caspase activation.
CONCLUSIONS—Our in vitro results indicate that HRECs
respond to cytokines rather than high glucose, suggesting that in
vivo diabetes–related endothelial injury in the retina may be due
to glucose-induced cytokine release by other retinal cells and not
a direct effect of high glucose. Diabetes 57:1952–1965, 2008
H
yperglycemia is a major causative factor in the
development of diabetic retinopathy. Several
biochemical pathways have been associated
with hyperglycemia, including glucose-medi-
ated increases in reactive oxygen species (ROS) (1),
diacylglycerol production, and the subsequent activation
of the protein kinase C pathway (2), ﬂux through the
polyol metabolic pathway (3), accumulation of advanced
glycation end products (4), and cytokine secretion (5).
Most of these results are based on studies using macro-
vascular cells (6), and these studies were never conﬁrmed
using microvascular endothelial cells from the end organs
affected by diabetic microvascular complications. Further-
more, although diabetic animal studies have supported
that chronic hyperglycemia generates ROS in the vascular
environment, the precise cellular origin of the ROS has not
been established (7).
It is well recognized that mitochondria are the main
source of endogenous ROS in most mammalian cell types
(8). Of the oxygen consumed by mitochondria, 1–5% is
converted to ROS as byproducts of oxidation-reduction
reactions in the respiratory chain. Small proportions of
ROS that escape antioxidant defenses lead to chronic
low-level oxidative damage to mitochondria, which accu-
mulates throughout life. This accumulation is intensiﬁed in
chronic disease states, such as diabetes, and during acute
stress and/or inﬂammation (9).
In addition to mitochondria, small quantities of ROS can
also be generated from other intracellular sources. For
example, neutrophil-type NADPH oxidase (10) and
NADPH-like enzymes (NOX) generate small quantities of
ROS in the absence of a speciﬁc stimulus in endothelial
cells (11). Cytokines, including tumor necrosis factor-
(TNF-), generate ROS that serve as essential second
messengers in normal intracellular signaling pathways, but
their overproduction can result in pathology (12).
The initiation and progression of diabetic retinopathy
has been attributed not only to hyperglycemia and ROS
but also to inﬂammation. The inﬂammatory response in
early diabetes includes cytokine release, which activates
key transcriptional regulators, including nuclear factor-B
(NF-B). NF-B in turn regulates expression of proinﬂam-
matory molecules, including inducible nitric oxide syn-
thase, cyclooxygenase (COX)2, and intracellular adhesion
molecule (ICAM). Increased expression of cell adhesion
molecules, such as ICAM, promotes leukostasis. These
conditions promote vascular permeability and ultimately
endothelial cell death (13).
When endothelial cells are exposed to interleukin (IL)-
1, TNF-, and interferon- (IFN-), they produce addi-
tional cytokines, such as IL-8, monocyte chemotactic
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1952 DIABETES, VOL. 57, JULY 2008protein-1 (MCP-1), and RANTES (regulated upon activa-
tion, normal T-cell expressed and secreted), among others,
that appear to be endothelial cell-type speciﬁc. Human
trials and animal studies using aspirin and other anti-
inﬂammatory agents demonstrate both prevention and
improvement of diabetic retinopathy, providing additional
support for the pathogenic role of cytokine-induced leu-
kocyte activation (14).
Although cytokine production, oxidative stress, and
glucose-induced vascular toxicity have all been implicated
as key causes of diabetic retinopathy, no detailed studies
have been performed to date to determine whether retinal
endothelial cell dysfunction is mediated primarily by di-
rect glucose toxicity or by direct cytokine toxicity. This
study was designed to address these critical questions and
to separate the vascular effects of high glucose from the
vascular effects of proinﬂammatory cytokines on human
retinal endothelial cells (HRECs).
RESEARCH DESIGN AND METHODS
Cell culture media, Alexa Fluor 488 acetylated LDL, and MitoTracker Red
were obtained from Invitrogen (Carlsbad, CA). Endothelial cell growth
supplement (ECGS) was from Upstate Biotechnology (Lake Placid, NY), and
insulin transferrin selenium mix (ITS), 7-amino-4-triﬂuoro-methylcoumarin
(AFC), and commonly used chemicals and reagents were from Sigma-Aldrich
(St. Louis, MO). TNF- and IL-1 were from R&D Systems (Minneapolis, MN).
The following antibodies were used: rabbit anti-human Von Willebrand factor
from Dako (Carpinteria, CA); rabbit anti–phospho-IB (Ser
32), rabbit anti–
inhibitor of B( I B) , and rabbit anti–phosphor-p44/42 mitogen-activated
protein kinase (MAPK) (Thr202/Tyr204) from Cell Signaling Technology
(Danvers, MA); rabbit anti–phosphor–stress-activated protein kinase (SAPK)/
Jun NH2-terminal kinase (JNK) (T183/Y185), rabbit anti–phosphor-p38(TGpY)
from Promega (Madison, WI); mouse anti-phosphotyrosine (4G10) from
Upstate Biotechnology; and mouse anti-actin and rabbit anti–c-FLIP antibody
from Sigma-Aldrich. Caspase substrates (AFC coupled) were from Calbio-
chem (San Diego, CA); IL-1 ELISA assays were from Pierce/Endogen
(Rockford, IL).
Cell culture
Tissue was provided by the National Disease Research Interchange (Philadel-
phia, PA), and primary HRECs, human retinal pigment epithelial cell (HRPEs),
and human Mu ¨ller cells (HMCs) were prepared and cultured as previously
described (15,16). Primary cultures of HRECs were obtained from at least
three separate donors. Passages 3–6 were used in the experiments. Purity of
the cells was determined using acetylated LDL uptake and Von Willebrand
factor staining. Only 99% and higher purity HREC preparations were used in
the study. HRECs were grown in six-well plates coated with 0.1% gelatin in 2
ml growth medium/well consisting of Dulbecco’s modiﬁed Eagle’s medium/
F12 (1:1 ratio, 5 mmol/l glucose) supplemented with 10% fetal bovine serum,
5% ECGS, 1% penicillin/streptomycin, and 1 ITS at 37°C in humidiﬁed 95% air
and 5% CO2 until fully conﬂuent. For experimental conditions, serum content
was decreased to 2%. Cells treated with 5 mmol/l glucose and 20 mmol/l
mannitol or L-glucose were used as an osmotic control. Medium was changed
every 72 h or every 12 h for experiments with glucose ﬂuctuations from 5 to
25 mmol/l concentrations. For cytokine treatment, HRECs were switched to
serum-free media for 12 h and treated with 0–10 ng/ml TNF- or 0–2 ng/ml
IL-1 for the times indicated in RESULTS.
For co-culture experiments, HRECs (1  10
6) were plated in six-well plates
containing growth medium. HMCs were plated in a HMC:HREC 1:50 ratio. The
co-culture was treated in medium containing 5 or 25 mmol/l glucose. After 48 h
of treatment, the cells were trypsinized with 0.05 mg/ml trypsin:EDTA for 30 s
to selectively collect HRECs. HRECs were lyzed in 100 mmol/l HEPES buffer,
pH 7.5, containing 10% sucrose, 0.1% CHAPS, and the general protease
inhibitors 1 mmol/l EDTA, 1 mmol/l phenylmethylsulfonyl ﬂuoride, and 10
g/ml leupeptin; sonicated for 10 s; and centrifuged at 9,000g for 5 min at 4°C,
followed by protein measurement of the supernatant. Supernatants were
retained for caspase experiments.
Glucose consumption rate
Cells were cultured in 5, 15, 20, or 25 mmol/l glucose. At the time points
indicated in RESULTS, an aliquot of medium was taken from each plate, and the
glucose concentration remaining in the medium was measured spectrophoto-
metrically using a hexokinase glucose-6-phosphate dehydrogenase enzymatic
assay kit from Sigma-Aldrich. Glucose consumption was explained by the
generalized reaction of A 3 B, where A is extracellular glucose and B is
consumed glucose. This reaction is described by the following equations:

	
A
	t
 k  [protein]forzeroorderkinetics, 
	
A]
	t
 k  [A]  [protein]for
ﬁrst order kinetics and 
	[A]
	t
 k  [A]
2  [protein] for second order kinetics,
where [A] is media glucose concentration, [protein] is total cellular protein, 	t is
time, and k is the rate constant (17). To evaluate the order of kinetics of glucose
consumption reaction 
	
A]
	t  [protein]
was plotted against [A]. Numerical value
of rate constant was subsequently determined by Nonlinear Least Squares
Regression at http://statpages.org/nonlin.html.
Detection of ROS in HRECs
Fluorescent ROS detection. 5-(and-6)-Chloromethyl-2,7 -dichlorodihy-
droﬂuorescein diacetate (CM-H2DCFDA) ROS indicator dye (Invitrogen) was
used. HRECs were plated in a ﬂat, clear bottom, 96-well plate at 10,000
cells/well and treated with varying glucose concentrations as described in
RESULTS. The cells were preloaded with 2 mol/l CM-H2DCFDA for 30 min
followed by ﬂuorescence measurement in a microplate reader (Molecular De-
vices, Downing, PA). A well containing no cells was subtracted as a background.
The cells from a sister well for each experiment were trypsinized and counted,
and the results were presented as ﬂuorescence per cell.
Spin-trap electron paramagnetic resonance. For electron paramagnetic
resonance (EPR) measurements, HRECs were cultured in matrix-coated
Teﬂon tubes (1-mm internal diameter) in 5, 15, or 25 mmol/l glucose for the
times indicated in RESULTS. Several spin traps with different principles of
detection were used. First, two commercially available spin traps, 5, 5-dim-
ethylpyrroline-N-oxide (DMPO) from Dojindo Laboratories (Kumamoto, Ja-
pan) and -phenyl-tert-butylnitrone (PBN) from Sigma-Aldrich were used. The
EPR silent DMPO or PBN reacts with intracellular radicals to produce stable
EPR-detectable DMPO or PBN radicals (see Fig. 3, top and middle). The
increase in the corresponding spin adduct intensity corresponds to the
amount of free radicals in the cell.
We also synthesized (according to Inoguchi et al. [18]) cell permeable spin
trap 4-acetoxymethylcarboxylate-2,2,6,6-tetramethylpiperidine 1-oxyl (TEM-
PO-AM). The EPR-detectable TEMPO-AM is hydrolyzed inside the cell,
retained in the cytoplasm, and then reduced to the corresponding hydroxyl-
amine, leading to the loss of paramagnetism (see Fig. 3, bottom). Thus, the loss
of EPR signal corresponds to the amount of intracellular free radicals. EPR
spectra were measured on a Bruker ESP 300E spectrometer equipped with a
Bruker ER4111VT variable-temperature accessory (Bruker, Rheinstetten, Ger-
many) using EPR cavity (4108 TMH). Data were analyzed using software
supplied by Bruker (ESP 1600 data system).
Mitochondrial superoxide production. HRECs (1  10
4 cells) were grown
on coverslips and incubated in treatment medium as described above. At
times indicated, the superoxide-speciﬁc MitoTracker Red solution was added
to the medium at a ﬁnal concentration of 500 mol/l, and cells were further
incubated in the dark for 20 min at 37°C/5% CO2. The medium was removed;
cells were washed twice with PBS (2 ml), ﬁxed in 4% paraformaldehyde for 10
min at room temperature, and washed twice with PBS (2 ml). Coverslips were
mounted on slides using an anti-fading ﬂuorescent mounting medium contain-
ing DAPI to stain for nuclei (Vector Shield). Digital Images were captured in
12 bits on a Leica DMI 6000 B inverted microscope using a Retiga EXI camera
(Q-Imaging, Vancouver, British Columbia, Canada) at 40 magniﬁcation
(MitoTrackerRed, excitation 580 nm, emission 600 nm; DAPI, excitation 359,
emission 461). Image analysis was performed using Metamorph Imaging
Software (Molecular Devices). Red intensity (arbitrary ﬂuorescence units
equivalent to mitochondrial superoxide production) was quantiﬁed, inte-
grated, and normalized to the integrated DAPI intensity (equivalent to cell
number). Results were represented as the ratio of arbitrary ﬂuorescence units
to integrated DAPI intensity.
SDS-PAGE and Western blot analysis
SDS-PAGE and Western blot analyses were performed as previously described
(19). Primary antibodies dilution was for c-FLIP, 1:800; phospho-IB, 1:500;
IB, 1:1,000; phosphor-p44/42, 1:1,000; phosphor-SAPK/JNK, 1:1,000; phos-
phor-p38, 1:500; and 4G10, 1:1,000. Secondary antibodies dilutions were
1:3,000. Western blots were quantitated by scanning densitometry using
ImageJ software ver. 1.29 (available by ftp at zippy.nimh.nih.gov/ or at
http://rsb.info.nih.gov/nih-image; developed by Wayne Rasband [National In-
stitutes of Health, Bethesda, MD]), and expression of protein of interest was
normalized to actin.
Electrophoretic mobility gel shift assay
The double-stranded oligonucleotide containing the NF-B binding sequence
derived from human vascular cell adhesion molecule-1 (VCAM-1) promoter
were designed and synthesized as follows: 5 TGCCCTGGGTTTCCCCTT
GAAGGGATTTCCCTC3 and 3GACCCAAAGGGGAACTTCCCTAAAGG
GAGGCGG5. The oligonucleotides were annealed and labeled in the presence
of [
32P]dCTP with a random primer kit from Invitrogen, according to the
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DIABETES, VOL. 57, JULY 2008 1953manufacturer’s protocol. For binding reactions, nuclear extracts (6 g) were
incubated in 25-l total reaction volume with
32P-labeled NF-B oligonucleotides
for 20 min at room temperature. DNA-protein complexes were resolved on 6%
nondenaturing polyacrylamide gels, and the bands were examined by autoradiog-
raphy. Incubation of the nuclear extracts with excess cold NF-B oligonucleo-
tides was used to conﬁrm the speciﬁcity of binding activity.
Caspase activity assay
Caspase activities were measured using ﬂuorogenic caspase substrate (DEVD-
AFC for caspase-3 and IETD-AFC for caspase-8) as described previously
(20,21). Caspase activity was calculated against an AFC standard curve and
expressed as picomoles AFC per milligram protein per minute.
Annexin V staining for apoptosis
Annexin V staining was done according to the manufacturer’s instruction as
previously described (16). HRECs staining positive for Annexin V were
counted and expressed as a percentage.
Cytokine measurement by ELISA
IL-1 and TNF- concentrations in the medium were determined using an
IL-1 or TNF- ELISA kit (Pierce/Endogen) according to the manufacturer’s
instructions as previously described (21).
Statistical analysis
Data are expressed as the mean 
 SD. Factorial ANOVA with post hoc Tukey’s
test (calculated using http://faculty.vassar.edu/lowry/VassarStats.html) was
used for comparing continuous data obtained from independent samples, and
Kruskal-Wallis with post hoc Dunn’s test was used for comparing Western blot
and imaging data. Signiﬁcance was established at P  0.05.
RESULTS
Glucose consumption by HRECs is not affected by
glucose concentration, unlike HRPEs and HMCs. We
determined the dependency of glucose consumption by
HRECs versus glucose concentration in the media. Plot of

	
A]
	t  [protein] versus [A] is presented in Fig. 1. Non-
linear least squares regression analysis demonstrated that
the dependency can be best ﬁtted by the equation Y 
175.09 
 2.17 nmol glucose  mg
1 protein  h
1 with
correlation coefﬁciency of 0.927, describing a zero-order
kinetics reaction (17). Thus, the rate of glucose consump-
tion in HRECs was not dependent on glucose concentra-
tion in the media. We then compared the amount of
glucose consumed in 24 h by HRECs, HRPEs, and HMCs
cultured in 5 and 25 mmol/l glucose. As presented in the
inset of Fig. 1, HRECs consumed extremely low amounts
of glucose compared with the other retinal cell types
examined. In contrast to HRPEs and HMCs, there was no
increase in glucose consumption in HRECs cultured in 25
mmol/l glucose. The increase in consumption by HRPEs
and HMCs was glucose speciﬁc because the osmotic
control mannitol did not increase consumption (data not
shown).
High glucose conditions do not induce ROS produc-
tion in HRECs. Using the CM-H2DCFDA ﬂuorescent ROS
indicator, we were able to observe weak baseline genera-
tion of endogenous ROS for cells incubated in normal (5
mmol/l) glucose. However, no increase in endogenous
H
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FIG. 1. Rate of glucose consumption in endothelial cells is not dependent on glucose concentration in media. Conﬂuent plates of HRECs were
cultured in 5 mmol/l (), 15 mmol/l (Œ), 20 mmol/l (F), or 25 mmol/l (f) glucose for 2, 4, 8, 16, 32, and 64 h. HRECs, HRPEs, and HMCs were
cultured in 5 mmol/l (white bars) or 25 mmol/l (black bars) glucose for 24 h (inset). Glucose consumption was determined as a rate of decrease
in glucose concentration in the media normalized to total cellular protein and plotted against glucose concentration in the media. Nonlinear least
squares regression analysis demonstrated that the dependency can be best ﬁtted by the equation Y  175.09  2.17 nmol glucose  mg
1 protein
 h
1 with correlation coefﬁciency of 0.927, describing a zero-order kinetics reaction. As presented in the inset, HRECs consumed extremely low
amounts of glucose compared with HRPEs and HMCs, and there was no increase in glucose consumption in HRECs cultured in 25 mmol/l glucose
unlike in the HRPE and HMC cultures. Results represent means  SD; n  3 for HRPEs, 4 for HMCs, and 6 for HRECs; *P < 0.05.
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diate (15 mmol/l) and high (25 mmol/l) glucose for up to
96 h (Fig. 2A). We examined the effect of ﬂuctuating
glucose between 5 and 25 mmol/l every 12 h on ROS
production because this would more closely represent
what can be observed in diabetic patients. As shown in
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FIG. 2. Measurements of oxidative stress in high glucose–treated HREC ﬂuorescent ROS indicators do not show production of oxidative radicals.
CM-H2DCFDA ﬂuorescent ROS indicator measurements were performed on HRECs treated with increasing glucose concentrations (5, 15, and 25
mmol/l) (n  3) (A) or on HRECs treated with ﬂuctuating glucose concentrations (B). The ﬂuorescence intensity was normalized to cell number
in normal 5 mmol/l glucose (white bars) or ﬂuctuating 5–25 mmol/l glucose every 12 h for the times indicated (black bars). Results of nine
independent experiments (means  SD) are shown. *P < 0.01 compared with 5 mmol/l glucose at 1, 24, and 72 h (white bars). #P < 0.01 25 mmol/l
glucose compared with 5 mmol/l glucose at 96 h. C: HRECs were incubated in medium containing 5 or 25 mmol/l glucose for times indicated.
Mitochondrial superoxide production was measured as described in RESEARCH DESIGN AND METHODS using MitoTrackerRed, a dye that accumulates
in the mitochondria and becomes ﬂuorescent upon reaction with superoxide radicals. Results are presented as the mean  SD (MitoTracker
Red/DAPI intensity; n  6). At time points indicated, representative ﬂuorescent images (40 objectives) of MitoTracker Red and DAPI overlay
are shown on the left.
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FIG. 3. Measurements of oxidative stress in high glucose–treated HRECs using spin trap EPR do not show production of oxidative radicals.
Spin-trap EPR was used to conﬁrm the failure of high glucose to increase endogenous ROS production by HRECs. HRECs were cultured in
matrix-coated Teﬂon tubes. In each experiment, the cells were incubated for 1–72 h in 5 (), 15 (), or 25 (‚) mmol/l glucose, and production
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of detection is shown on the left, representative EPR traces in the middle, and quantitated data on the right. Cells stimulated with 0.5 mmol/l
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(). Top and middle: Traces A for DMPO and PBN are from 25 mmol/l glucose-stimulated cells. No cells control and 5 and 15 mmol/l glucose traces
looked similar to 25 mmol/l glucose trace. Traces B for DMPO and PBN are from the positive control. In DMPO and PBN experiments, exposure
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tween cultures maintained only at 5 mmol/l and cultures
that were exposed to ﬂuctuating glucose concentrations of
5 mmol/l for 12 h and then 25 mmol/l glucose for the next
12 h. This ﬂuctuating pattern was continued for 96 h. Only
by 96 h was a change observed, but this was not due to an
increase in ROS in the ﬂuctuating group but rather to a
decrease in ROS production in 5 mmol/l group. We also
monitored ROS generation using MitoTrackerRed, a dye
that accumulates in the mitochondria and becomes ﬂuo-
rescent upon reaction with superoxide radicals. No
change in endogenous ROS production was observed with
high glucose treatment of HRECs in either short-term (up
to 144 h) or long-term (4 weeks) exposure to high glucose
(Fig. 2C).
To conﬁrm the failure of high glucose to increase
endogenous ROS production by HRECs, we developed a
more sensitive spin-trap EPR approach. In each experi-
ment, the cells were incubated for 1–72 h in 5, 15, or 25
mmol/l glucose and DMPO- or PBN-radical production was
measured. Cells stimulated with 0.5 mmol/l H2O2 in the
presence of iron to induce Fenton’s reaction served as a
positive control. Exposure to 15 and 25 mmol/l glucose did
not cause detectable radical production (no cells control,
5, 15, and 25 mmol/l glucose graphs are super-imposable;
Fig. 3, top and middle). Although only 24-h data are shown,
the rest of the time points produced similar results. Only
when the cells were stimulated with H2O2 was radical
production observed.
We then used the even more sensitive EPR-detectable
TEMPO-AM spin trap. TEMPO-AM is hydrolyzed inside the
cell, retained in the cytoplasm, and then reduced to the
corresponding hydroxylamine, leading to the loss of para-
magnetism (Fig. 3, bottom). Thus, the loss of EPR signal
corresponds to the amount of intracellular free radicals.
HRECs were incubated for 1–96 h in the varying glucose
concentrations, and then TEMPO-AM was added. HRECs
exposed to 5, 15, or 25 mmol/l glucose for 24 h demon-
strated a low level of radicals, and there was no difference
in radical production between different glucose concentra-
tions. Incubation of the cells with glucose over all time
points produced similar results (data not shown). When
the cells were stimulated with H2O2, radical production
was detected as a loss of paramagnetism. As expected,
Teﬂon tubes without cells show no loss of paramagnetism
(Fig. 3, bottom, ).
High glucose does not affect MAPK signaling in
HRECs. Because hyperglycemia is the key metabolic
mediator associated with diabetes, we examined the effect
of high glucose on all major MAPK pathways in HRECs.
Exposure to high glucose (25 mmol/l) for 10 min to 96 h
did not affect phosphorylation status of extracellular
signal–related kinase (ERK)1/2, p38, or JNK MAPKs
(Fig. 4A and B). The 24-, 72-, and 96-h time points for 25
mmol/l glucose are shown; shorter time points, interme-
diate (15 mmol/l) glucose concentration, and L-glucose
osmotic control produced similar results (results not
shown).
To determine the effect of high glucose on activation
of NF-B pathway, an electrophoretic mobility shift
assay (EMSA) was performed in HRECs after high
glucose (25 mmol/l) exposure for 48 h and 4 weeks. A
double-stranded DNA probe containing the speciﬁc
NF-B binding site from human VCAM-1 promoter was
used to study the activation and binding of NF-Bt ot h e
promoters of adhesion molecules. As shown in Fig. 4C,
high glucose exposure did not induce NF-B binding to
the VCAM-1 promoter. In contrast to high glucose,
stimulation with 1 ng/ml IL-1 for 30 min induced a
robust 3.5 increase in NF-B binding to the VCAM-1
promoter.
High glucose induced only low-level activation of
proapoptotic caspases. Apoptosis of retinal endothelial
cells has been demonstrated in vivo (22) and ultimately
results in formation of acellular capillaries. Several pro-
apoptotic initiator caspases, such as capase-2, -8, and -9,
are known to trigger apoptotic events. Therefore, we
examined high glucose–induced activation of these pro-
apoptotic initiator caspases. Caspase-8 was the only initi-
ator caspase that became activated, and its activity
increased slightly by 38 
 4.3% at 96 h and 40 
 1.9% by
144 h (Fig. 5A). Western blot analysis conﬁrmed activation
of capase-8 indicated by cleavage of caspase-8 zymogen
(55 kDa) (Fig. 5A). Interestingly, the initiator caspase-9, a
caspase associated with mitochondria-mediated apopto-
sis, was not activated (data not shown). To further conﬁrm
that mitochondria-mediated apoptosis was not induced by
high glucose, we examined protein levels of the proapop-
totic bcl2 family member bax and the anti-apoptotic bcl2.
Protein levels of both bcl2 family members were un-
changed in high glucose–treated HRECs compared with
control (data not shown).
A major regulator of caspase-8 signaling and inhibitor of
apoptosis is the family of c-FLIP proteins. In HRECs, the
c-FLIPL (or -isoform) (55 kDa) is the dominant isoform.
Western blot analysis showed that HRECs have high levels
of c-FLIPL protein (Fig. 5B). Decrease of pro-survival
c-FLIPL was evident at 96 h of high glucose exposure, a
time point at which caspase-8 activation occurs, suggest-
ing that c-FLIPL needs to be deactivated before caspase-8
activation can occur.
Next, we characterized the downstream effect of high
glucose on the activation of executioner caspases, such as
caspase-3, to conﬁrm that the weak activation of caspase-8
led to the execution of cell death of HRECs. Caspase-3
activity showed a slight but signiﬁcant increase over time
by 15 
 0.5 and by 18 
 0.5% at 96 and 144 h, respectively,
compared with control (Fig. 5C, left). At 144 h, high
glucose induced 9.3 
 1.1% cell death in HRECs compared
with control cells (4.2 
 2.1%) as measured by Annexin V
staining (n  5). Interestingly, no signiﬁcant increase in
caspase-3 activity was observed in HRECs exposed to 25
mmol/l glucose for 4 weeks compared with control, indi-
cating that HRECs are highly capable of adapting to high
glucose conditions (Fig. 5C, right).
super-imposable in the top and middle panels. Only when the cells were stimulated with H2O2 was radical production observed (E). Bottom:
TEMPO-AM is more sensitive than DMPO and PBN and is hydrolyzed inside the cell, retained in the cytoplasm, and then reduced to the
corresponding hydroxylamine, leading to the loss of paramagnetism. Loss of EPR signal corresponds to the amount of intracellular free radicals.
HRECs were incubated for 1–96 h in the varying glucose concentrations, and then TEMPO-AM was added. HRECs exposed to 5 (), 15 (), or
25 (‚) mmol/l glucose for 24 h all demonstrated a low level of radicals, and there was no difference in radical production between different glucose
concentrations. Trace A for TEMPO-AM is from no cell control with no loss of paramagnetism; trace B is from 25 mmol/l glucose; 5 and 15 mmol/l
glucose traces looked similar to 25 mmol/l glucose; trace C is from positive control with radical production being detected as a loss of
paramagnetism. Results of ﬁve independent experiments (mean  SD) are shown in the graphs.
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caspase-1 or lead to production and release of proin-
ﬂammatory cytokines by HRECs. We next investigated
whether elevated glucose increased the production and
release of proinﬂammatory cytokines. Incubation of
HRECs for 24 up to 144 h in high glucose did not induce
proinﬂammatory caspase-1 activation, the enzyme re-
quired to generate mature IL-1. Caspase-1 activity in
HRECs exposed to normal glucose conditions ranged from
40.1 
 0.8 (24 h) up to 42.9 
 0.9 pmol AFC  mg
1  min
1
(144 h) over time. Caspase-1 activity in HRECs treated in
high glucose ranged from 39.4 
 1.0 pmol (24 h) up to
43.4 
 1.1 pmol AFC  mg
1  min
1 (144 h) over time. In
addition, HRECs did not produce and release the proin-
ﬂammatory cytokines IL-1 and TNF- as measured by
ELISA when incubated in high glucose for 4 up to 96 h
(data not shown).
High glucose induces IL-1 in HRPEs and HMCs. To
determine whether high glucose induces inﬂammatory
mediators by neighboring cells, we measured IL-1 pro-
duction in HRPEs and HMCs exposed to high glucose. In
sharp contrast to endothelial cells, exposure of HRPEs
and HMCs to high glucose for 4 h induced marked increase
in IL-1 production. For HRPEs, IL-1 production showed
an 10-fold increase from 5.4 
 4.2 pg  ml
1  mg
1
protein in 5 mmol/l glucose to 50.1 
 12.1 in 25 mmol/l
glucose (P  0.05). For HMCs, IL-1 production increased
10-fold from 20.4 
 8.5 in 5 mmol/l glucose to 246.6 

36.3 pg  ml
1  mg
1 protein in 25 mmol/l glucose (P 
0.05).
IL-1 increases glucose consumption and subsequent
mitochondrial superoxide production in HRECs. In
contrast to high glucose (shown in Fig. 1), exposure of
HRECs cultured in normal 5 mmol/l glucose to 1 ng/ml
IL-1 for 6 h induced a 2.38-fold increase in glucose
consumption (Fig. 6A). In addition, the same treatment
induced a threefold increase in mitochondrial oxidative
stress (Fig. 6B) compared with normal and high glucose
treatment (Fig. 2B).
Cytokines induce MAPK phosphorylation and IB
phosphorylation and degradation in HRECs. Because
high glucose conditions did not activate or stimulate
HRECs in any of the assays we tested thus far, we next
examined the direct effect of TNF- and IL-1 on HRECs.
HRECs were exposed to 5 ng/ml TNF- or 1 ng/ml IL-1
for 0–30 min. Both cytokines induced marked ERK1/2 and
JNK phosphorylation (Fig. 7A).
IL-1, but not high glucose, induces tyrosine phos-
phorylation in HRECs. In addition to MAPK protein,
tyrosine kinases play an important role in activation of
inﬂammatory and apoptotic signaling cascades. The effect
of high glucose and cytokine exposure on tyrosine phos-
phorylation in HRECs was next examined. Stimulation
with 0.5 mmol/l H2O2 for 10 min was used as a positive
control. HRECs were treated with high glucose for 0.5–78
h with or without 1 ng/ml IL-1. IL-1 was added for the
last 10 min before harvesting the cells. As expected,
stimulation with 0.5 mmol/l H2O2 for 10 min as well as 1
ng/ml IL-1 led to a marked increase in tyrosine-phospho-
rylated proteins in HRECs (Fig. 7B). However, exposure to
high glucose for 0.5–78 h did not change the tyrosine
phosphorylation status of HRECs (24-h data shown, other
time points produced similar results).
Cytokines, but not high glucose conditions, induce
NF-B pathway in HRECs. Activation of the NF-B
pathway initiates an inﬂammatory response in retinal
endothelium (23). Thus, the effect of high glucose condi-
tions, TNF-, and IL-1 on the ﬁrst step in NF-B pathway
activation, namely IB phosphorylation and degradation,
was examined. High glucose had no effect, whereas 5
ng/ml TNF- or 1 ng/ml IL-1 for 0–30 min led to a
dramatic increase in IB phosphorylation and degrada-
tion (Fig. 7C).
Activation of caspases in HRECs by cytokines. As
demonstrated above, HRECs are very responsive to cyto-
kine exposure. IL-1 (1 ng/ml) under normoglycemic con-
ditions activated caspase-8 (Fig. 8A) and dramatically
decreased protein levels of c-FLIPL after 12-h treatment, as
shown by Western blot analysis (Fig. 8B, right lane). In
comparison, c-FLIPL levels were only moderately de-
creased after 96 h of high glucose incubation (Fig. 8B, left
lane). In contrast to high glucose treatment, cytokine
treatment induced the activities of a variety of caspases,
such as caspase-2 (31.3 
 7.1 pmol AFC  mg
1  min
1),
caspase-6 (35.9 
 5.9 pmol AFC  mg
1  min
1), and
caspase-9 (13.0 
 10.3 pmol AFC  mg
1  min
1), com-
pared with control (17.0 
 12.4, 24.0 
 8.7, and 0.8 
 6.4
pmol AFC  mg
1  min
1, respectively), indicating the
activation of a mitochondria-mediated apoptotic pathway,
which is further supported by the presence of mitochon-
drial superoxide production as shown in Fig. 6B.
As expected, 1 ng/ml IL-1 effectively increased HREC
caspase-3 activity by 234 
 13.2% compared with control
(Fig. 8C, left) within 12 h. To test the inﬂuence of high
glucose on the effect of cytokine treatment on caspase-3
activity, HRECs were treated with 1 ng/ml IL-1 in high
glucose conditions. High glucose did not alter the effect of
cytokine treatment alone on caspase-3 activation (Fig. 8C,
left), indicating that high glucose has neither priming nor
protective effect. To test whether other retinal cell types
known to release cytokines after high glucose treatment,
such as HMCs, have an effect on HREC viability, HRECs
were co-cultured with HMCs in 5 and 25 mmol/l glucose
for 48 h. Caspase-3 activities of HRECs cultured alone or
co-cultured with HMCs in different glucose conditions
were measured. Only co-culture of HRECs with HMCs in
high glucose led to a signiﬁcant increase in caspase-3
activity (53.1 
 4.5 pmol AFC  mg
1  min
1) in HRECs
(Fig. 8C, right), indicating that high glucose–stimulated
HMCs are causing a detrimental effect on HRECs.
DISCUSSION
Our in vitro results suggest that HRECs respond to cyto-
kines rather than high glucose for ROS generation, induc-
tion of inﬂammatory pathways, and apoptotic changes.
Our studies suggest that in vivo diabetes–related endo-
thelial injury in the retina may be primarily due to gluco-
se-induced cytokine release by neighboring cells rather
than a direct effect of high glucose on endothelial cells
themselves.
A number of studies have demonstrated that glucose-
induced oxidative stress and cytokine production in the
retina are associated with diabetic retinopathy (7,24–27).
However, before the current study, it was not clear
whether endothelial dysfunction is a primary effect of
direct glucose toxicity in retinal endothelial cells or a
secondary effect mediated by cytokines. In this study, we
systematically compared the effects of elevated glucose
levels to the effects of two key cytokines on various
parameters associated with endothelial cell toxicity using
HRECs as a model.
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FIG. 4. High glucose does not lead to MAPK phosphorylation and NF-B activation in HRECs. HRECs were incubated in either 5 or 25 mmol/l
glucose for designated time periods. Immunoblot analyses using anti–phospho-ERK1/2, anti–phospho p38, and anti–phospho JNK antibodies was
performed. Equal amounts of protein were added to each lane as conﬁrmed by actin levels. Exposure to high glucose (25 mmol/l) for 24, 72, and
96 h did not affect phosphorylation status of ERK1/2, p38, or JNK MAPKs. Representative results from at least three independent experiments
are shown in the left (A). Densitometry analysis of Western blots (normalized to actin, n  3) are presented as mean  SD in B. C: NF-B EMSA
gel shift assays were performed on HRECs treated with 5 or 25 mmol/l glucose for times indicated. IL-1 (1 ng/ml) treatments served as positive
controls. Representative image of NF-B gel shift is show in C; densitometry analysis of three independent EMSA assays is shown in D.
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very low level of glucose consumption compared with
other retinal cell types, HRPEs and HMCs, from the same
donors. Moreover, the rate of glucose consumption by
HRECs was independent of glucose concentration in the
media. There are a number of parameters that can affect
glucose toxicity in different cell types. Among them are
expression and regulation of different types of glucose
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FIG. 5. High glucose induces slight activation of proapoptotic caspase signaling pathways in short-term but not in long-term treatments. A: HRECs
were incubated in medium containing 5 or 25 mmol/l glucose. Activities of caspase-8, the only initiator caspase that became activated, are
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In HRECs, the c-FLIPL (or -isoform) (55 kDa) is the dominant isoform of this family of caspase-8 signaling regulator and apoptosis inhibitor.
Western blot analysis showed that HRECs have high levels of c-FLIPL protein (55 kDa), and high glucose (25 mmol/l) treatment induces loss of
c-FLIPL. This Western blot is representative of three independent experiments. Densitometry analysis of the Western blots is presented as the
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ysis versus oxidative phosphorylation, antioxidant protec-
tion level, and differential response to insulin. As we and
others described before, the predominant glucose trans-
porter in HRECs is GLUT1 with minor GLUT3 expression
level (15,28,29). The expression level of these transporters
was not controlled by high glucose in HRECs in our
studies; moreover, the rate of glucose consumption ob-
served in this study (175.09 nmol  mg protein
1  h
1) was
below the Vmax for glucose uptake observed by us in high
glucose in HRECs (56.00 pmol  mg protein
1  s
1 
201.60 nmol  mg protein
1  h
1) (15). Taken together,
these data suggest that glucose consumption in HRECs is
not likely to be limited by glucose uptake rate but rather
by further glucose metabolism steps.
If HRECs do not increase glucose consumption under
high glucose conditions, there is no reason to expect
glucose-induced radical production by these cells. We
performed repeated tests using H2DCFDA ROS indicator
dye, MitoTracker Red mitochondrial O2
-speciﬁc probe,
and three different spin traps for EPR measurements:
DMPO, PBN, and TEMPO-AM, all of which were negative
for high glucose–induced radical production by HRECs.
Similarly, high glucose had no effect on MAPK protein
phosphorylation signaling cascades, namely ERK1/2, p38,
and JNK phosphorylation, on tyrosine phosphorylation or
on activation of NF-B pathway. High glucose also did not
induce caspase activation or apoptosis for the ﬁrst 96 h of
glucose exposure. Only after 96–144 h of exposure did we
detect a modest induction of caspases and a minor amount
of apoptosis. Only caspase-8 and caspase-3 were activated
in HRECs by elevated glucose levels, indicating a type I
caspase signaling pathway, which requires upstream
caspase-8 activation followed by direct downstream acti-
vation of caspase-3. Caspases and other proapoptotic
proteins involved in the mitochondrial death pathway
were unaffected by high glucose. This is consistent with
the ﬁndings that ROS formation and mitochondrial O2

production were not increased in high glucose because
mitochondria-mediated apoptosis requires the production
of O2
 within the mitochondria itself to release cytochrome
c from the mitochondrial membrane (30). A major regula-
*
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FIG. 6. IL-1 increases glucose consumption and subsequent mitochondrial superoxide production in HRECs. A: HRECs were incubated in
medium containing 5 mmol/l glucose (white bar) or 5 mmol/l glucose  1 ng/ml IL-1 (black bar) for 6 h, and glucose consumption was measured
as described in RESEARCH DESIGN AND METHODS. Results are presented as the mean  SD; n  5, *P < 0.05. B: HRECs were incubated in medium
containing 5 mmol/l glucose or 5 mmol/l glucose  1 ng/ml IL-1  for 6 h. Mitochondrial superoxide production was measured as described in
RESEARCH DESIGN AND METHODS. Results are presented as the mean  SD (MitoTracker Red/DAPI intensity; n  6) with *P < 0.05 signiﬁcantly
different from normal glucose. Representative ﬂuorescent images (40 objectives) of MitoTracker Red and DAPI overlay are shown on the left.
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tested. HRECs were serum starved overnight and stimulated with 5 ng/ml TNF- or 1 ng/ml IL-1 for different time periods as indicated. The
activation of ERK and JNK signaling pathways was assessed by immunoblot analyses using anti–phospho-ERK1/2 and anti–phospho JNK
antibodies as indicated. Equal amounts of protein were added to each lane as conﬁrmed by actin levels. Both cytokines induced marked ERK1/2
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1962 DIABETES, VOL. 57, JULY 2008tor of caspase-8 activation is the protein c-FLIP. c-FLIPs
are well-known inhibitors of cell death. To date, three
isoforms of the protein have been identiﬁed, c-FLIPL,
c-FLIPS, and c-FLIPR. All isoforms are structurally similar
to caspase-8 but do not have a catalytically active site
serving as an alternative substrate for caspase-8 (31). High
glucose–induced caspase-8 activation only occurred after
c-FLIPL levels declined, indicating that apoptosis observed
in HRECs was associated with the reduction of c-FLIPL.
Interestingly, although caspase-3 was slightly but signiﬁ-
cantly activated in HRECs by high glucose at 144 h, this
activation of caspase-3 seems to be transient. Long-term
exposure of HRECs in high glucose up to 4 weeks did not
lead to increased caspase-3 activity or cell death, indicat-
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FIG. 8. IL-1 induces activation of caspase-8 and -3, and loss of protective c-FLIPL in HRECs. A: HRECs were incubated in medium containing 5
mmol/l glucose or 1 ng/ml IL-1 for 12 h. Activities of caspase-8 were measured and presented as means  SD (n  6) with *P < 0.05 signiﬁcantly
different from normal glucose. B: IL-1 strongly decreased protein levels of pro-survival c-FLIPL within 12 h compared with 96 h incubation in
25 mmol/l glucose and control as shown by Western blot analysis in HRECs. The Western blot is representative of three independent experiments.
Densitometry analysis of the Western blots is presented as the mean  SD of the c-FlipL–to–actin ratio (n  3) with *P < 0.05 signiﬁcantly
different from normal glucose. C: HRECs were treated in 5 or 25 mmol/l glucose in the presence or absence of IL-1 (1 ng/ml) for 12 h, and
caspase-3 activities were measured (left). High glucose did not inﬂuence caspase-3 activity in a synergistic manner. Caspase-3 activities are
presented as means  SD (n  6) with *P < 0.05 signiﬁcantly different from normal glucose. HRECs were cultured alone or in co-culture with
HMCs in 5 or 25 mmol/l glucose for 48 h as described in RESEARCH DESIGN AND [SCAP]METHODS (right). Caspase-3 activities of HRECs either cultured
alone or in HREC/HMC co-culture were measured and presented as means  SD (n  6) with *P < 0.05 compared with HRECs treated in 5 mmol/l
glucose.
anti-phospho-tyrosine antibody after treatment with high glucose for 0.5–78 h with or without IL-1 (1 ng/ml). Stimulation for 10 min with either
0.5 mmol/l H2O2 (positive control) or 1 ng/ml IL-1 led to a marked increase in tyrosine-phosphorylated proteins. Twenty-four–hour exposure
data are shown; similar results were obtained for 0.5- to 78-h time points. C: The effects of high glucose (top) conditions, TNF-, and IL-1
(bottom image) on IB phosphorylation and degradation, the ﬁrst step in NF-B pathway activation, were examined in HRECs. High glucose had
no effect, whereas 5 ng/ml TNF- or 1 ng/ml IL-1 for 0–30 min led to a dramatic increase in IB phosphorylation and degradation.
Representative results from at least three independent experiments are shown on the left and quantiﬁed and presented as means  SD on the
right.* P < 0.01 compared with control.
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glucose conditions.
Overall, we found that HRECs were remarkably unre-
sponsive to intermediate, high, and ﬂuctuating glucose
conditions in various assays associated with endothelial
cell toxicity used in this study.
A prominent feature of diabetic retinopathy is increased
levels of proinﬂammatory cytokines in the retina, and
several inﬂammatory pathways are activated at the early
stage of diabetic retinopathy. Diabetes leads to the activa-
tion of caspase-1, the enzyme responsible for the produc-
tion of the proinﬂammatory cytokines IL-1 and IL-18 in
the retinas of diabetic animals and diabetic patients
(20,21,27). IL-1 can induce IL-6, TNF-, and itself (32).
IL-1 and TNF- have many overlapping physiological
functions. Both have also been associated with the induction
of oxidative stress and the mitochondrial death pathway (33).
Cytokines, such as TNF-, its soluble receptor, and IL-1, are
increased in serum of diabetic patients, and increased TNF-
levels have been associated with the development of diabetes
complications (34–36). Furthermore, increases in TNF- and
IL-1 levels have been shown in vitreous ﬂuid of diabetic
patients and in retinas of streptozotocin-induced diabetic rats
and mice (26,35,36).
Endothelial cells are extremely susceptible to cytokines,
such as IL-1, TNF-, and IFN-, which induce production
of endothelial cell–derived cytokines (e.g., IL-8, MCP-1,
and RANTES), recruitment of leukocytes to the cell sur-
face, and cell death (37,38). They are also very responsive
to cytokine stimulation, leading to ICAM-1 and VCAM-1
upregulation, as we have previously shown (19,23). In the
current study, we demonstrated that high glucose did not
induce caspase-1 activation, the enzyme responsible for
IL-1 production, and did not lead to the production and
release of IL-1 and TNF- by HRECs. In contrast, we have
shown that IL-1 induced more than a twofold increase in
glucose consumption and mitochondrial O2
 generation in
HRECs, whereas glucose alone did not. We also show that
IL-1 is a potent inducer of caspase-3 activity and apopto-
sis in HRECs. After 12 h of IL-1 stimulation, we detected
a 234% increase in caspase-3 activity compared with control,
an activation never reached with high glucose alone at any
given time point in these cells. In contrast to high glucose
treatment, IL-1 led to the activation of caspases involved in
the mitochondrial type II death pathway and was preceded
by the formation of mitochondrial oxidative stress required
for mitochondrial-mediated apoptosis. Anti-apoptotic
c-FLIPL levels were dramatically decreased by IL-1, indicat-
ing that HRECs might be very well protected against hyper-
glycemia but seem to be less able to protect themselves
against proinﬂammatory stress.
In addition to retinal endothelial cells, almost all other
cell types in the retina are known to be adversely affected
in diabetes. These include pericytes, microglia, astrocytes,
HMCs, and HRPEs cells, as well as retinal neural element,
such as ganglion cells, bipolar cells, and photoreceptors
(rev. in 39). Any of these cells could be the actual source
of the glucose-induced cytokine production. In this study,
we used two examples, HRPEs and HMCs, to demonstrate
the principle of potential involvement of other retinal cell
types in glucose-induced toxicity. In agreement with other
studies, our results demonstrate that HMCs and HRPEs
produce proinﬂammatory cytokines, such as IL-1,i n
response to elevated glucose (21,40). HRPEs and HMCs
are known to produce growth factors and neuroactive
peptides (41) that maintain endothelial health; however,
pathologically high levels of growth factors and cytokines
can exist during diabetes and during retinal ischemia
(42–44). Because HMCs are known to encircle the micro-
vasculature, protecting the integrity of the microvascula-
ture, the likelihood of cytokines produced by HMCs
reaching endothelial cells is very possible (45). Our study
indicates that high glucose–induced stimulation of HMCs
might have detrimental effects on the vasculature. But
again, most other retinal cell types surrounding the vascu-
lature can possibly affect endothelial cell viability in the
similar fashion.
Although glucose-induced ROS expression by endothe-
lial cells has been reported by others (18,46–48), out-
comes are highly dependent on experimental conditions
and the vascular bed and the species of origin of the
endothelial cells (49). Perhaps more important is that cell
types typically contaminating retinal endothelial cultures,
such as HMCs, HRPEs, pericytes, microglia, and astro-
cytes, may be the actual source of the glucose-induced
cytokine production measured previously in retinal endo-
thelial cell cultures. HRPEs and HMCs exposed to high
glucose produced 2.5 and 12.3 ng/ml IL-1, respectively,
which is 2.5- to 12.3-fold higher than the 1 ng/ml IL-1
required for stimulation of endothelial cells. Thus, cyto-
kines secreted by these cells could in turn stimulate
endothelial cell ROS production, apoptosis, activation of
MAPK signaling cascades, tyrosine phosphorylation,
NF-B pathway activation, and adhesion molecules ex-
pression. We have extensively published studies using
primary HREC cultures and only HRECs of 99% or higher
purity, as were used in the current study.
In conclusion, our in vitro studies show that high
glucose conditions do not increase endogenous ROS gen-
eration by HRECs but rather that these cells respond to
cytokines that upregulate ROS. Furthermore, our in vitro
studies also suggest that in vivo retinal endothelial injury
resulting in capillary drop-out and the retinal pathology
associated with diabetic retinopathy may be due primarily
to glucose-induced cytokine release by neighboring cells
rather than the direct effect of high glucose on endothelial
cells.
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